Abigail Davis
Obstetrics & Gynecology · Caldwell, OHNPI 1588913958
Payments from drug & device makers
Across 119 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$238
- Astellas Pharma US Inc$209
- Sumitomo Pharma America, Inc.$164
- Exeltis, USA Inc.$163
- Evofem Biosciences, Inc.$153
- Mylan Pharmaceuticals Inc.$140
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,05495%
- Education$1025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $238 |
| Astellas Pharma US Inc | 8 | $209 |
| Sumitomo Pharma America, Inc. | 9 | $164 |
| Exeltis, USA Inc. | 10 | $163 |
| Evofem Biosciences, Inc. | 10 | $153 |
| Mylan Pharmaceuticals Inc. | 7 | $140 |
| Organon | 9 | $131 |
| Bayer | 5 | $103 |
| Exact Sciences | 4 | $89 |
| Therapeuticsmd, Inc. | 5 | $69 |
| Pfizer | 4 | $68 |
| Dexcom, Inc. | 3 | $66 |
| Hologic Sales And Service, LLC | 4 | $63 |
| Merck | 3 | $59 |
| Heron Therapeutics, Inc. | 4 | $55 |
| Myovant Sciences Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Sage Therapeutics, LLC | 2 | $49 |
| Convatec Inc. | 2 | $46 |
| Optumhealth Care Solutions, LLC | 3 | $42 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Novo Nordisk | 1 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Smith+Nephew | 1 | $21 |
| Aspira Women's Health Inc | 1 | $17 |
| AstraZeneca | 1 | $16 |
How this compares
$2,157 in reported general payments places this provider in the 75th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 19 | $1,654 |
| Estradiol | 22 | $1,470 |
| Fluocinonide | 14 | $391 |
| Mometasone Furoate | 18 | $186 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Caldwell
- Margaret RheeAkron$19.6M
- Harold GreenColumbus$2.3M
- Stuart WeprinEnglewood$1.2M
- Abner CorderoTiffin$985K
- Jeffrey MangelCleveland$886K
- Angelina GangestadCleveland$744K
- Gerard ReillyCincinnati$582K
- Sarah ArtmanHilliard$512K
- Samir AhujaMentor$430K
- David SheynCincinnati$330K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.